exendin-4   Click here for help

GtoPdb Ligand ID: 1135

Synonyms: AC 2993 | AC002993 | AC2993A | Bydureon® | Byetta®
Approved drug
exendin-4 is an approved drug (FDA (2005), EMA (2006))
Comment: This peptide is found in the venom of the Gila monster Heloderma suspectum. Exenatide is the synthetic form of the peptide used in clinical practice. Exendin-4 is a GLP-1 analogue/mimetic [1]. There is some ambiguity surrounding the exact stereochemistry of exendin-4. Representations of the peptide's full chemical structure can be accessed using the PubChem, ChEMBL and ChEBI links that we provide in the Database Links table.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: exenatide

No information available.
Summary of Clinical Use Click here for help
Approved to treat type 2 diabetes mellitus (T2DM) in patients whose blood sugar is inadequately controlled by other antidiabetes medicines (e.g. metformin, sulphonylureas, thiazolidinediones) or basal insulin. An extended-release formulation for once-weekly administration by injection (called Bydureon® BCiseTM) was FDA approved in October 2017, and as of April 2018 can be used as an adjunct to basal insulin therapy in adults with (T2DM), with or without metformin.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Acts as a GLP-1 receptor agonist and mimics the action of endogenous GLP-1 peptide in controlling blood sugar levels via improved insulin and glucagon secretion and decreased food intake.
External links Click here for help